Guggenheim analyst Vamil Divan initiated coverage of Alpine Immune Sciences with a Buy rating and $55 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALPN:
- Alpine Immune Sciences Announces New Chief Accounting Officer
- Biotech Alert: Searches spiking for these stocks today
- Vera Therapeutics price target raised to $34 from $21 at Wedbush
- Alpine Immune Sciences’ Growth at Risk: Navigating FDA and SEC Disruptions Amidst Political and Health Uncertainties
- Alpine Immune Sciences price target raised to $47 from $30 at Morgan Stanley